[Hepatitis B cure drugs are expected to be approved for marketing in China by the end of this year or early 2027] On October 23, the U.S. Food and Drug Administration (FDA) recently officially approved Hibsago (bepirovirsen) injection developed by GlaxoSmithKline (GSK). Combined with existing antiviral therapies, it is used to treat some adult patients with chronic hepatitis B (HBV) infection without cirrhosis. The results of the III clinical trial of this drug show that when HBsAg (hepatitis B virus surface antigen, a key indicator for determining whether they are infected with hepatitis B virus) ≤3000 Among adult patients with IU/ml, the functional cure rate reached 19%. Current standard treatment options typically result in functional cure rates of less than 1% after one year. Industry estimates indicate that the new drug is expected to be approved for marketing in China by the end of this year or early 2027. (China Business News)